[Treatment of chronic alcoholic pancreatitis with a new acid-resistant pancreatin product].
The authors summarised pathophysiology and therapy possibility of the chronic alcoholic pancreatitis. They introduce a new product of pancreatin use for treatment of chronic alcoholic pancreatitis. The aim of this prospective study was to asses the efficacy of this new drug in the treatment of chronic alcoholic pancreatitis. The treatment was carried out by new pancreatin product containing 10,000 FIP U lipase, 9000 FIP U amylase, and 500 FIP E protease. During the study 30 patients--suffering from alcoholic pancreatitis--were treated. They received, two tablets three times daily in a period of two weeks. The following parameters were observed and compared before and after the period of treatment: complaints of the patients, the characteristics of the stool (daily weight, frequency, fat contents, consistency) the change of the body weight and degree of abdominal pain. These parameters were compared using a score-system, before and after the period of treatment. The authors could analyse the data of 21 patients. It was proved that there was a significant decrease in frequency, daily weight and fat contents of the stool and in abdominal pain. There was not significant change in the body weight. The authors concluded that this new product is a good pancreatin preparation which is useful and suitable for effective treatment of chronic alcoholic pancreatitis, if the patient keeps abstinence.
Kempelen
I
I
Fövárosi Onkormányzat Bajcsy-Zsilinszky Kórház, Budapest.
Szilárd
M
M
D000437:Alcoholism / Q000150:complications*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D010194:Pancreatin / Q000627:therapeutic use*; D010195:Pancreatitis / Q000139:chemically induced* / Q000188:drug therapy
D010194:Pancreatin
Az alkoholos eredetü idült hasnyálmirigy-gyulladás kezelése újabb savrezisztens pancreatin készítménnyel.